Publication|Articles|September 2, 2026
- MHE September 2026
- Volume 36
- Issue 9
Product Profile: Simtriyo (centanafadine)
The FDA approved July 2026 Simtriyo, a new type of medication for patients with attention-deficit hyperactivity disorder (ADHD).
Advertisement
Learn about a new product for ADHD.
Articles in this issue
about 2 months ago
Agentic AI may take humans out of the loopabout 2 months ago
Rural health is ailing. Is $50 billion enough to heal it?3 months ago
What Argentina can teach U.S. healthcare leadersAdvertisement
Advertisement
Advertisement